Financial Constraints to Molecular Biomarker Testing

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.

Related Videos

October 23, 2018

Best Practices in Oncology Biomarker Testing

Drs. Goeffrey Oxnard and Lauren Ritterhouse review the best practices to improve efficiencies in biomarker testing, including effective communication among the healthcare team, the pathologist, and the patient, as well as expediting processing in the pathology laboratory.

March 31, 2015

New Targets = Better Standard of Care

Alexander Bastian mentions that looking at more defined populations and leveraging the power of targeted medicine is improving the standard of care.